EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieVergleichsstudieOpen Access · CC BY 4.0

Remimazolam-etomidate versus remimazolam-propofol for gastrointestinal endoscopy: A randomized controlled trial

Baoyu Ma iD, Ning Zhang, Rong Huang, Shoushi Wang iD

PLOS One · 2025

DOI: 10.1371/journal.pone.0326043 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift PLOS One, 2025. Verfasst von Baoyu Ma und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology and Perioperative Medicine, Qingdao Central Hospital, University of Health and Rehabilitation Sciences (Qingdao Central …. Hauptthemen laut MEDLINE: Propofol, Endoscopy, Gastrointestinal, Etomidate, Benzodiazepines. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

The optimal sedation strategy for gastrointestinal endoscopy remains debated. This study compared the efficacy and safety of remimazolam combined with etomidate versus propofol for procedural sedation during gastrointestinal endoscopy.

Methods

This single-center, randomized controlled clinical trial was performed from March 2024 to April 2024. A total of 262 patients scheduled to undergo gastrointestinal endoscopy were randomly assigned to receive remimazolam-etomidate (RE) or remimazolam-propofol (RP). The primary outcome was the incidence of respiratory depression. Secondary outcomes included the results of sedation and recovery. The safety results mainly include the incidence of hypotension, bradycardia, tachycardia, painful injection and muscular tremor. Statistical analyses included t-tests, Mann-Whitney U tests, and χ² tests for group comparisons, with subgroup analyses and multivariable logistic regression to assess the robustness of primary outcome.

Results

Respiratory depression occurred in 20.0% (25/125) of RE patients versus 32.3% (40/124) of RP patients (OR=0.52; 95% CI = 0.29–0.93; p = 0.028). There was a statistically significant difference in the distribution of the number of airway interventions between the two groups ( p = 0.043), with 18 patients (14.5%) in the RP group requiring three airway interventions and only seven patients (5.6%) in the RE group. Hypoxemia occurred in three patients (2.4%) in the RE group and in five patients (4.0%) in the RP group. Hypotension was observed in 23.2% of patients sedated with RE versus 36.3% of patients sedated with RP ( p = 0.024).

Conclusion

Remimazolam-etomidate demonstrated a superior safety profile, with reduced respiratory depression and hemodynamic instability compared to remimazolam-propofol, suggesting its potential as a safer alternative for gastrointestinal endoscopy sedation. Registration information This trial was prospectively registered at the Chinese Clinical Trial Registry (ChiCTR2400085904) prior to patient enrollment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PropofolEndoscopy, GastrointestinalEtomidateBenzodiazepinesHypnotics and SedativesHumansFemaleMaleMiddle AgedAgedAdult

Substanzen

PropofolremimazolamEtomidateBenzodiazepinesHypnotics and Sedatives

Autor:innen und Institutionen

  • Department of Anesthesiology and Perioperative Medicine, Qingdao Central Hospital, University of Health and Rehabilitation Sciences (Qingdao Central Medical Group), Qingdao, China.

ORCID-Profile: Baoyu Ma, Shoushi Wang

Zitieren

APA

Ma, B., Zhang, N., Huang, R., & Wang, S. (2025). Remimazolam-etomidate versus remimazolam-propofol for gastrointestinal endoscopy: A randomized controlled trial. PLOS One. https://doi.org/10.1371/journal.pone.0326043

Vancouver

Ma B, Zhang N, Huang R, Wang S. Remimazolam-etomidate versus remimazolam-propofol for gastrointestinal endoscopy: A randomized controlled trial. PLOS One. 2025. doi:10.1371/journal.pone.0326043

BibTeX
@article{Ma2025,
  author = {Ma, Baoyu and Zhang, Ning and Huang, Rong and Wang, Shoushi},
  title = {Remimazolam-etomidate versus remimazolam-propofol for gastrointestinal endoscopy: A randomized controlled trial},
  journal = {PLOS One},
  year = {2025},
  doi = {10.1371/journal.pone.0326043}
}
Kostenlos starten →